{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:14:56Z","timestamp":1780841696874,"version":"3.54.1"},"reference-count":52,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence and incidence of atrial fibrillation\/flutter (AF\/AFL) in patients with human immunodeficiency virus type\u20101 (HIV\u20101) infection have been poorly investigated. We performed a systematic review using PubMed and Cochrane Database of Systematic Reviews, and screening of references, searching for clinical studies reporting on the association between HIV\u20101 infection and AF\/AFL. We also summarized the main interactions of antiretroviral agents with antithrombotic and antiarrhythmic drugs. We found a prevalence of AF\/AFL ranging from 2.0% to 5.13% in patients with HIV\u20101, with an incidence rate of 3.6\/1000 person\u2010years. Low CD4+ count (&lt;200\u2013250\u00a0cells\u00a0ml<jats:sup>\u22121<\/jats:sup>) and high viral load were predictors of AF\/AFL. Regarding drugs interactions, nucleoside reverse transcriptase inhibitors, integrase inhibitor and maraviroc have the lowest interactions with oral anticoagulants. Among anticoagulants, dabigatran presents the most favourable profile. Most of antiarrhythmic drugs interact with protease inhibitors, with beta blockers and diltiazem having fewer interactions. The few studies available suggest a non\u2010negligible prevalence of AF\/AFL in patients with HIV\u20101 infection. Awareness of potential interactions with anticoagulation and antiarrhythmic drugs is needed to offer optimal management in this population.<\/jats:p>","DOI":"10.1111\/bcp.13837","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T22:26:53Z","timestamp":1545431213000},"page":"508-515","source":"Crossref","is-referenced-by-count":18,"title":["Atrial fibrillation and human immunodeficiency virus type\u20101 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy"],"prefix":"10.1111","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Mezzaroma","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-7455","authenticated-orcid":false,"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6610-7068","authenticated-orcid":false,"given":"Francesco","family":"Violi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart &amp; Chest Hospital  Liverpool UK"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine Aalborg University  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30066-8"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.6698"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/569819"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60948-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199912240-00002"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2010.10.018"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e3283562a27"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6830"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001469"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2015.01.005"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.05.012"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001450"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001560"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001470"},{"key":"e_1_2_7_17_1","volume-title":"The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses","author":"Wells GA","year":"2014"},{"key":"e_1_2_7_18_1","first-page":"404","article-title":"Risk factors for the development of atrial fibrillation in HIV infected patients","volume":"4","author":"Elnahar Y","year":"2012","journal-title":"J Atr Fibrillation"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.022"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194754"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441003"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy617"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08736-x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000416"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euw161"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv274"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq066"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.12.060"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu013"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep31042"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006402"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-12-0923"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(02)00258-4"},{"key":"e_1_2_7_34_1","first-page":"1112","article-title":"Mechanisms and management of thrombo\u2010embolism in atrial fibrillation","volume":"7","author":"Violi F","year":"2014","journal-title":"J Atr Fibrillation"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-11-0876"},{"key":"e_1_2_7_36_1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1160\/TH-17-10-0709","article-title":"Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)","volume":"117","author":"Lip GYH","year":"2017","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3040745"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903493458"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014523115"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000412"},{"key":"e_1_2_7_41_1","first-page":"125","article-title":"Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine","volume":"66","author":"Bates D","year":"2013","journal-title":"Can J Hosp Pharm"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv309"},{"key":"e_1_2_7_43_1","unstructured":"The Canadian HIV\/AIDS Pharmacists Network (CHAP).A management tool for HIV drug\u2013drug interactions[online]. Available athttps:\/\/hivclinic.ca\/downloads\/DDI%20tool_English_final.pdf(last accessed 28 December 2018)."},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.01.004"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200307040-00026"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462416661437"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.02.008"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18308"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2715"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e328365ca31"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000452"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"e_1_2_7_53_1","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents \u2013 A Working Group of the Office of AIDS Research Advisory Council (OARAC).Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents[online]. Available athttps:\/\/aidsinfo.nih.gov\/guidelines(last accessed 28 December 2018)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13837","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:30:10Z","timestamp":1694341810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/bcp.13837"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13837","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]}}}